MAP2K7 and melanoma: Although there is no inhibitor that acts directly on YAP1 in use in the clinic because of the unstructured nature of YAP1 21, the combinatorial use of indirect inhibitors of YAP1 and MEK inhibitor may serve as an alternative avenue for melanoma treatment.